PATENT COOPERATION TREATY

INTERNATIONAL SEARCHING AUT	HORITY			
To: JOSEPH M. KINSELLA, JR. FACTOR & LAKE, LTD. 1327 W. WASHINGTON BLVD. SUITE 5G/H		PCT WRITTEN OPINION OF THE		
CHICAGO, IL 60607		INTERNATIONAL SEARCHING AUTHORITY		
			(PCT Rule 43bis.1)	
		Date of mailing (day/month/year)	09 FEB 2006	
Applicant's or agent's file reference	-	FOR FURTHER ACTION		
IOM-P054PCT			See paragraph 2 below	
International application No.	International filing date	(day/month/year)	Priority date (day/month/year)	
PCT/US05/06437	28 February 2005 (28.02	.2005)	27 February 2004 (27.02.2004)	
International Patent Classification (IPC)	or both national classificati	on and IPC	2. 2 40100.) 2004 (27.02.2004)	
IPC(7): A61N 1/30 and US C1.: 604/20				
Applicant				
IOMED, INC.				
1. This opinion contains indications rel	lating to the following items			
Box No. I Basis of the	_			
Box No. II Priority	o opinion			
		ard to novelty, inve	ntive step and industrial applicability .	
Box No. IV Lack of uni	ty of invention		•	
Box No. V Reasoned st	tatement under Rule 43 <i>bis.</i> I y; citations and explanations	(a)(i) with regard to s supporting such st	o novelty, inventive step or industrial	
1 1	uments cited	0		
Box No. VII Certain defe	ects in the international appl	iaatian		
	ervations on the international			
2. FURTHER ACTION				
If a demand for international preliming International Preliminary Examining	he IPEA and the chosen IP	pt that this does EA has notified the	be considered to be a written opinion of the not apply where the applicant chooses an e International Bureau under Rule 66.1bis(b) red.	
If this opinion is, as provided above, IPEA a written reply together, where of Form PCT/ISA/220 or before the er For further options, see Form PCT/ISA	expiration of 22 months from		EA, the applicant is invited to submit to the iration of 3 months from the date of mailing whichever expires later.	
3. For further details, see notes to Form F				
Name and mailing address of the ISA/ US	Date of completion	of this opinion 1	Authorized officer	
Mail Stop PCT, Attn: IS A/US Commissioner for Patents				
P.O. Box 1450	22 January 2006 (2	22.01.2006)	Manuel Mendez	
Alexandria, Virginia 22313-1450 acsimile No. (571) 273-3201] 1	Telephone No. 703-000-000 0	
rm PCT/ISA/237 (cover sheet) (April 2005	5)	·· <u></u> <u>-</u>		

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US05/06437

Box No. 1 Basis of this opinion
1. With regard to the language, this opinion has been established on the basis of: the international application in the language in which it was filed a translation of the international application into, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
a. type of material
a sequence listing
table(s) related to the sequence listing
b. format of material
on paper in electronic form
c. time of filing/furnishing
contained in the international application as filed.
filed together with the international application in electronic form.
furnished subsequently to this Authority for the purposes of search.
In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:
•
rm PCT/ISA/237(Box No. 1) (April 2005)

90/587429 IAP11 Rec'd PCT/PTO 26 JUL 2006

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US05/06437

Industrial applicability (IA) Claims 1-48	. Statement			
Inventive step (IS) Claims 1-48 Claims NONE Industrial applicability (IA) Claims 1-48 Claims NONE	Novelty (N)	Claims	1-48	3
Claims NONE Industrial applicability (IA) Claims 1-48 Claims NONE Citations and explanations: Citations 1-48 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest, a platform, a dailor, a conductor, a dose controller, a drug delivery matrix wherein the conductor, the matrix, and the dose controller cooperate diverse a drug to a user when the electrode is affixed to the user and operably connected with the iontophoretic drug delivery systems. Claims 1-48 meet the criteria set out in PCT Article 33(4) and thus have industrial applicabilities to the criteria set out in PCT Article 33(4) and thus have industrial applicabilities to the criteria set out in PCT Article 33(4) and thus have industrial applicabilities to the criteria set out in PCT Article 33(4) and thus have industrial applicabilities to the criteria set out in PCT Article 33(4) and thus have industrial applicabilities to the criteria set out in PCT Article 33(4) and thus have industrial applicabilities to the criteria set out in PCT Article 33(4) and thus have industrial applicabilities to the criteria set out in PCT Article 33(4) and thus have industrial applicabilities to the criteria set out in PCT Article 33(4) and thus have industrial applicabilities to the criteria set out in PCT Article 33(4) and thus have industrial applicabilities to the criteria set out in PCT Article 33(4) and thus have industrial applicabilities to the criteria set out in PCT Article 33(4) and thus have industrial applicabilities to the criteria set out in PCT Article 33(4) and thus have industrial applicabilities to				Y
Claims NONE Industrial applicability (IA) Claims 1-48 Claims NONE Citations and explanations: Cita	Inventive step (IS)	Claima	1.40	
Industrial applicability (IA) Claims 1-48 Claims NONE Citations and explanations: Laims 1-48 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest, a platform, a tainer, a conductor, a dose controller, a drug delivery matrix wherein the conductor, the matrix, and the dose controller cooperate drug to a user when the electrode is affixed to the user and operably connected with the iontophoretic drug delivery systems. In the criteria set out in PCT Article 33(4) and thus have industrial applicability.	arrenave step (18)			Y
Citations and explanations: laims 1-48 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest, a platform, a tainer, a conductor, a dose controller, a drug delivery matrix wherein the conductor, the matrix, and the dose controller cooperate drug to a user when the electrode is affixed to the user and operably connected with the iontophoretic drug delivery systems. 1-48 meet the criteria set out in PCT Article 33(4) and thus have inductive a prelimitation.				N
Citations and explanations: laims 1-48 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest, a platform, a tainer, a conductor, a dose controller, a drug delivery matrix wherein the conductor, the matrix, and the dose controller cooperate drug to a user when the electrode is affixed to the user and operably connected with the iontophoretic drug delivery systems. 1-48 meet the criteria set out in PCT Article 33(4), and thus have industrial analysis to the criteria set out in PCT Article 33(4).	Industrial applicability (IA)			Y
laims 1-48 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest, a platform, a tainer, a conductor, a dose controller, a drug delivery matrix wherein the conductor, the matrix, and the dose controller cooperate liver a drug to a user when the electrode is affixed to the user and operably connected with the iontophoretic drug delivery systems. In the criteria set out in PCT Article 33(4) and thus have inductive and instance and the criterial set out in PCT Article 33(4) and thus have inductive and instance and the criterial set out in PCT Article 33(4).		Claims	NONE	N
laims 1-48 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest, a platform, a tainer, a conductor, a dose controller, a drug delivery matrix wherein the conductor, the matrix, and the dose controller cooperate liver a drug to a user when the electrode is affixed to the user and operably connected with the iontophoretic drug delivery systems. 1-48 meet the criteria set out in PCT Article 33(4) and thus have inductive and instance of the criterial set out in PCT Article 33(4).	Citations and explanations:			
	laims 1-48 meet the criteria set out in PCT Article	i to the user and t	perably connected with the ionto	phoretic drug delivery system
	made or used in industry.		,	and analysis matter staining
				•
	•			

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.